Tirzepatide: 22,104 Matched Bariatric-Surgery Patients
A retrospective US database study has reported lower recorded 90-day cardiovascular and kidney-event risks after metabolic and bariatric surgery among people with prior GLP-1 receptor agonist or Tirzepatide exposure. After propensity-score matching, the analysis included 11,052 people in each group. The association is notable because it concerns the period after surgery, but it does not demonstrate that the prior prescriptions caused the observed differences.
The study compared adults undergoing metabolic and bariatric surgery between 2016 and 2025 in the US Medical Records Database. Prior use meant at least one GLP-1RA or tirzepatide prescription between 365 and 7 days before surgery. People prescribed either class closer than seven days to surgery were excluded. That definition matters: the paper studies recorded prior exposure, not a medication strategy initiated immediately around an operation.
How the groups were compared
The authors matched prior users and non-users one to one with propensity scores. This statistical approach attempts to align observed baseline variables between groups before outcomes are compared. After matching, both cohorts contained 11,052 participants. The authors describe the baseline characteristics as well balanced.
Matching can improve a database comparison, but it is not random assignment. Medical records cannot fully capture every factor that may influence a prescription, a decision to proceed with surgery, follow-up intensity or a later complication. Diet, care pathways, disease severity and events treated outside the contributing network are examples of information that may be incompletely measured. For that reason, the result is an association in a particular dataset, not a test of a perioperative protocol.
The primary outcome was a four-component major adverse cardiovascular-event measure, assessed from postoperative day 1 through day 90. A key secondary outcome was early postoperative kidney events over the same window. The report also describes coronary events and heart failure as secondary outcomes.
What the researchers recorded
For the four-component cardiovascular outcome, 36 people in the prior-use group had an event, compared with 67 in the matched non-user group. The reported risks were 0.3% and 0.6%, respectively, with a hazard ratio of 0.535 and a 95% confidence interval of 0.357 to 0.803.
Early kidney events were recorded in 158 people in the prior-use group and 256 non-users. Those proportions were 1.4% and 2.3%, with a hazard ratio of 0.613 and a 95% confidence interval of 0.502 to 0.747. The authors also report lower observed risks of coronary events and heart failure in the prior-use cohort.
These figures describe two matched groups, not a result specifically attributable to tirzepatide. The exposure definition combined GLP-1 receptor agonists and tirzepatide, so the study cannot isolate a compound-specific estimate. The absolute number of cardiovascular events was also small, even in a large cohort. Both points shape what can responsibly be inferred from the findings.
Why the timing is central
The seven-day exclusion before surgery is a defining part of the design. It avoids blending the question of prior exposure with immediate preoperative medication management, but it also means the paper does not answer questions about how a compound should be handled near an operation. The authors instead ask whether a history of recorded use within the prior year is associated with later short-term outcomes after matching.
The study period spans several years, during which prescribing patterns, eligibility rules and surgical care may have changed. Propensity matching addresses variables included in the model, but it cannot account for changes that were not recorded or measured. A prospective study with a prespecified exposure plan would be needed to test causation.
Research context, not clinical direction
Tirzepatide is a dual GIP/GLP-1 agonist, while the study’s exposure group also included GLP-1 receptor agonists. This is why a combined database signal should not be read as evidence about every incretin-related compound. The Tirzepatide research buyer guide is a research-material resource, not a surgical-use recommendation.
Likewise, Retatrutide has a separate receptor profile and research record. Its background is covered in the Retatrutide research reference hub, not in this comparative surgical analysis. Peptra Labs material remains within a Research Use Only boundary. For wider reference material, see Best Research Peptides 2026.
The measured conclusion is narrow. In 22,104 matched patients, prior recorded use of a GLP-1RA or tirzepatide was associated with fewer 90-day cardiorenal events after metabolic and bariatric surgery. The large matched sample is a strength, while combined exposure categories and residual confounding mean that the result should be treated as a hypothesis-generating observational finding.
References
- Tseng TC, Chang R. Prior GLP-1RA or Tirzepatide Use and Early Cardiorenal Outcomes After Metabolic and Bariatric Surgery. The American Journal of Medicine. 2026. PubMed
- Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behavioral Research. 2011. Article
- National Institute of Diabetes and Digestive and Kidney Diseases. Bariatric surgery for severe obesity. NIDDK overview
The products referenced on this site are supplied for laboratory research use only. They are not medicines and are not intended for human or veterinary use. This article summarises published research for informational purposes and is not medical advice. Statements about third-party studies belong to their authors.
